Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: SG who wrote (17608)	1/27/2004 9:39:30 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 48461

I was in the warrants from a bit higher level.... TASR $139!!!!!

To: SG who wrote (17608)	1/31/2004 10:36:15 AM
From: Bucky Katt	Respond to of 48461

Good article in Barron's about TASR, should cause it to do one of two things, either selloff or spike up next week.... Bull's Eye, but . . . By RHONDA BRAMMER FORGIVE US, PLEASE, but we're feeling kind of confessional. It all has to do with a stock we really messed up on. Nope -- It wasn't a company we wrote skeptically about whose stock took off. Or even a company whose prospects we lauded that fell on hard times and whose stock fell even harder. It was, as it happens, a company we never wrote about at all. Taser International. We missed it entirely, even though we heard about the company back in the spring of 2003, when the stock was around $6. And we cottoned to the story instantly, we really did. Taser markets stun guns, mostly to law-enforcement types. The concept was intriguing: Stun guns, instead of the lethal kind, could reduce injuries for both cops and bad guys, in the process slashing the huge legal liabilities incurred in wrongful-death suits, not to mention avoiding a lot of the bad publicity and political heat that sort of thing engenders. The company, to be sure, was a pure spec -- an unseasoned enterprise with a spotty history and a minuscule market cap of under $20 million. Still, the product, as we say, looked like a comer and, icing on the cake, the company had an okay balance sheet and even a smidgen of earnings. Indeed, the savvy pro who brought it to our attention reckoned in a year, the stock could sell at $15, maybe higher. But before we'd had a chance to do our homework -- in the space of less than three weeks -- the shares jumped a cool 50%. So we shelved the financials and waited for the stock to retreat. We're still waiting. _________ The rest of the story> online.wsj.com